Nucleocapsid protein enhances spike- and RBD-specific humoral and cellular immune responses in protein-based SARS-CoV-2 vaccine.

Saved in:
Bibliographic Details
Title: Nucleocapsid protein enhances spike- and RBD-specific humoral and cellular immune responses in protein-based SARS-CoV-2 vaccine.
Authors: Gröhn S; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Lehto H; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Soppela S; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Naves RA; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Nordic SARS Response AB, Stockholm, Sweden., Ritvos MA; Nordic SARS Response AB, Stockholm, Sweden.; School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden., Iakubovskaia A; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Lampinen V; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Mustonen I; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Pakkala S; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Husu E; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Kakkola L; Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.; Clinical Microbiology, Turku University Hospital, Turku, Finland., Julkunen I; Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.; Clinical Microbiology, Turku University Hospital, Turku, Finland.; InFlames Research Flagship Center, University of Turku, Turku, Finland., Kolehmainen P; Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland., Pasternack A; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Nordic SARS Response AB, Stockholm, Sweden., Ritvos O; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Hankaniemi MM; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. minna.hankaniemi@tuni.fi.
Source: BMC infectious diseases [BMC Infect Dis] 2026 Jan 29; Vol. 26 (1). Date of Electronic Publication: 2026 Jan 29.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1471-2334
DOI:10.1186/s12879-026-12634-x